Serum biomarkers in patients with relapsing eosinophilic granulomatosis with polyangiitis (Churg-Strauss).
| Autor: | Christian Dejaco, Bastian Oppl, Paul Monach, David Cuthbertson, Simon Carette, Gary Hoffman, Nader Khalidi, Curry Koening, Carol Langford, Kathleen McKinnon-Maksimowicz, Philip Seo, Ulrich Specks, Steven Ytterberg, Peter A Merkel, Jochen Zwerina |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2015 |
| Předmět: | |
| Zdroj: | PLoS ONE, Vol 10, Iss 3, p e0121737 (2015) |
| Druh dokumentu: | article |
| ISSN: | 1932-6203 11893516 |
| DOI: | 10.1371/journal.pone.0121737 |
| Popis: | Previous studies suggest a role for eotaxin-3, TARC/CCL17 and IgG4 in newly-diagnosed patients with eosinophilic granulomatosis with polyangiitis (EGPA, Churg-Strauss) with highly active disease. The role of these biomarkers in relapsing disease is unclear.Serum levels of TARC/CCL17, eotaxin-3, IgG4, and IgG4/IgG ratio were determined in serum samples from a longitudinal cohort of patients with EGPA (105 visits of 25 patients). Epidemiological, clinical and laboratory data were available for all visits.At the first visit, 80% of patients were using glucocorticoids and 68% additional immunosuppressive drugs. Disease flares were seen at 18 visits. The median BVAS and BVAS/WG scores at time of relapse were 4 and 2, respectively. None of the biomarkers tested were useful to discriminate between active disease and remission. Patients treated with prednisone had lower eotaxin-3 and eosinophil levels compared to patients not taking glucocorticoids irrespective of disease activity. Use of immunosuppressive agents was not associated with biomarker levels.Serum levels of TARC/CCL17, eotaxin-3, IgG4, and IgG4/IgG ratio do not clearly differentiate active and inactive disease in established EGPA. Defining biomarkers in EGPA remains a challenge especially during times of glucocorticoid use. |
| Databáze: | Directory of Open Access Journals |
| Externí odkaz: |
|